SIMCOR tablets contain niacin extended-release (NIASPAN) and simvastatin in combination. Simvastatin, an inhibitor of HMG-CoA reductase, and niacin are both lipid-altering agents.
Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.
Patients with Hypercholesterolemia Requiring Modifications of Lipid Profiles
SIMCOR is indicated to reduce total-C, LDL-C, Apo B, non-HDL-C, TG, or to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia when treatment with simvastatin monotherapy or niacin extended-release monotherapy is considered inadequate.
SIMCOR is indicated to reduce TG in patients with hypertriglyceridemia when treatment with simvastatin monotherapy or niacin extended-release monotherapy is considered inadequate.
Limitations of use
No incremental benefit of SIMCOR on cardiovascular morbidity and mortality over and above that demonstrated for simvastatin monotherapy and niacin monotherapy has been established.
Published Studies Related to Simcor (Simvastatin / Niacin)
Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered
with extended-release niacin in hyperlipidemic patients. 
CONCLUSIONS: These results suggest that E/S+N improves lipoprotein particle
Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects. [2011.05]
BACKGROUND: Efforts to lower plasma lipid levels sometimes require multiple agents with different mechanisms of action to achieve results specified by national treatment guidelines... CONCLUSION: There is a small pharmacokinetic drug interaction between ER niacin and ezetimibe/simvastatin and although this is not considered to be clinically significant, the concomitant use of these drugs should be appropriately monitored, especially during the niacin titration period.
Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy. [2010.11.24]
OBJECTIVE: To compare the effects of combination niacin extended-release + simvastatin (NER/S) versus atorvastatin alone on apolipoproteins and lipid fractions in a post hoc analysis from SUPREME, a study which compared the lipid effects of niacin extended-release + simvastatin and atorvastatin in patients with hyperlipidemia or mixed dyslipidemia... CONCLUSION: NER/S treatment significantly improved apo A-I levels and the apo B:A-I ratio, significantly lowered the number of atherogenic LDL particles and VLDL and chylomicron particles, and increased the mean size of LDL and VLDL particles, compared with atorvastatin.
Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. [2010.02.15]
The safety and efficacy of combination ezetimibe/simvastatin (E/S) plus extended-release niacin was assessed in 942 patients with type IIa/IIb hyperlipidemia for 64 weeks in a randomized, double-blind study. Patients received E/S (10/20 mg) plus niacin (to 2 g) or E/S (10/20 mg) for 64 weeks, or niacin (to 2 g) for 24 weeks and then E/S (10/20 mg) plus niacin (2 g) or E/S (10/20 mg) for an additional 40 weeks...
Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy. [2009.04]
BACKGROUND: Niacin has multiple lipoprotein effects that may provide cardiovascular benefit when added to statin monotherapy... CONCLUSIONS: We demonstrate that full-dose niacin/moderate-dose simvastatin combination has sustained benefits on atherogenic apoB lipoproteins, at least comparable to high-dose simvastatin, while also raising HDL-cholesterol. Results of large clinical trials will inform whether niacin-statin combinations reduce cardiovascular disease events.
Clinical Trials Related to Simcor (Simvastatin / Niacin)
Myocardial Protection Effect of Simvastatin Undergoing Cardiac Surgery [Recruiting]
Statins have been used to low cholesterol to prevent and treat coronary artery diseases. It
was also reported that statins could protect endothelial function and cardiac function
during coronary artery bypass graft. We recent found simvastatin reduced myocardial injury
during noncoronary artery cardiac surgery in single medical center. We further investigate
that whether simvastatin can protect myocardium during noncoronary artery cardiac surgery
with cardiopulmonary bypass and improve cardiac function with long term use postoperatively
in two medical centers.
Effect of Simvastatin on Cardiac Function [Completed]
It is well know that statins have been used to low cholesterol to prevent and treat coronary
artery disease for many years. It was also reported that statins could protect endothelial
function and cardiac function during coronary artery bypass graft. However, some results
were controversial. Also, there is no clinical data available on statin cardiac protection
during surgery in China where rheumatic heart disease is prevalent. Thus, the investigators
are trying to see whether statins can protect heart injury during cardiac surgery in
Chinese. Part of patients will receive statin treatment and part of will not before surgery
in the study. Both patients' heart function will be measured and compared after surgery to
determine whether statins can protect heart injury during heart surgery.
An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME) [Completed]
To demonstrate that niacin ER and simvastatin (NS) tablets, when compared to atorvastatin
(LipitorŪ; Pfizer, Inc.), has superior high-density lipoprotein cholesterol (HDL-C)
elevating effects at Week 12 in subjects with type II hyperlipidemia or mixed dyslipidemia
who are currently off lipid-modifying therapy. This was a prospective, randomized,
open-label, blinded endpoint (PROBE) study.
Reports of Suspected Simcor (Simvastatin / Niacin) Side Effects
Feeling Hot (207),
Skin Burning Sensation (110),
Burning Sensation (65),
Blood Glucose Increased (54),
Myalgia (41), more >>
Page last updated: 2014-11-30